DRW Securities LLC Has $312,000 Stock Holdings in Intuitive Surgical, Inc. $ISRG

Key Points

• DRW Securities LLC has decreased its holdings in Intuitive Surgical by 71.4%, now owning 631 shares worth approximately $312,000.
• Analysts have raised their price targets for Intuitive Surgical, with Wells Fargo increasing it from $559 to $599 and Truist Financial from $590 to $600, while the stock maintains a consensus rating of "Moderate Buy".
• Intuitive Surgical reported $2.19 earnings per share for the last quarter, exceeding expectations and achieving a 21.4% revenue growth year-over-year.

DRW Securities LLC lowered its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 71.4% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 631 shares of the medical equipment provider's stock after selling 1,574 shares during the period. DRW Securities LLC's holdings in Intuitive Surgical were worth $312,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. Chilton Capital Management LLC raised its stake in Intuitive Surgical by 614.3% in the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 43 shares in the last quarter. Global Financial Private Client LLC increased its holdings in shares of Intuitive Surgical by 253.3% during the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 38 shares during the period. Elite Financial Inc. bought a new position in shares of Intuitive Surgical during the first quarter worth approximately $26,000. LFA Lugano Financial Advisors SA acquired a new stake in shares of Intuitive Surgical in the first quarter valued at approximately $30,000. Finally, TD Capital Management LLC boosted its stake in shares of Intuitive Surgical by 300.0% in the first quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock valued at $30,000 after buying an additional 45 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Amy L. Ladd sold 335 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $440.69, for a total value of $147,631.15. Following the sale, the director directly owned 739 shares in the company, valued at $325,669.91. This represents a 31.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Myriam Curet sold 4,500 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the sale, the executive vice president directly owned 353 shares of the company's stock, valued at $173,845.44. This represents a 92.73% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 45,440 shares of company stock worth $21,838,124. Corporate insiders own 0.70% of the company's stock.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG traded up $13.34 during midday trading on Thursday, hitting $454.52. 3,938,868 shares of the stock were exchanged, compared to its average volume of 1,868,338. The business's 50-day moving average price is $495.33 and its 200 day moving average price is $514.32. Intuitive Surgical, Inc. has a 12 month low of $425.00 and a 12 month high of $616.00. The stock has a market capitalization of $162.94 billion, a price-to-earnings ratio of 63.39, a P/E/G ratio of 4.62 and a beta of 1.61.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, topping the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The business had revenue of $2.44 billion for the quarter, compared to the consensus estimate of $2.35 billion. During the same period last year, the company earned $1.78 EPS. The firm's revenue was up 21.4% compared to the same quarter last year. As a group, sell-side analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Wall Street Analyst Weigh In

ISRG has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft restated a "sell" rating on shares of Intuitive Surgical in a research note on Friday, August 22nd. Royal Bank Of Canada restated an "outperform" rating and issued a $615.00 price target on shares of Intuitive Surgical in a research report on Tuesday, August 19th. BTIG Research increased their price objective on shares of Intuitive Surgical from $566.00 to $571.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Zacks Research cut shares of Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 20th. Finally, Wells Fargo & Company increased their price target on shares of Intuitive Surgical from $559.00 to $599.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 23rd. Thirteen equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $595.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.